Clinicians have recognized for years that some individuals get lots of plaque and calculus, but experience little loss of periodontal support. Other patients seem to have really clean mouths, but experience extensive bone loss. Their disease is not so much related to the presence of bacteria but to some other factor. Within the past two years, a genetic marker has been identified that can be correlated with the degree of tissue destruction that occurs in some periodontal patients with advanced disease.
Genetic testing for periodontal disease susceptibility hinges on measuring a gene which regulates the production of an inflammation mediator called Interleukin 1B. Interleukin 1B, which is produced in response to a bacterial challenge, is a strong stimulator of host cells which destroy bone and soft tissue in an attempt to limit the spread of infection. When gum tissue is invaded by bacteria the extent of the bone and soft tissue damage is related to the intensity of the host cell response rather than on the quantity of bacteria challenging the system. The intensity of the response is determined by individual genetic makeup which dictates the amount of interleukin 1B cells produce in response to a bacterial challenge. The more of the interleukin 1B that is produced the greater the bone and soft tissue damage. Currently, only smoking overrides this genetic risk marker as a determinant of periodontal disease.
The genetic test that has been developed to determine your risk for periodontal disease is called PST (for periodontal sensitivity testing). It is a simple saliva test which is processed by a commercial laboratory in Flagstaff, Arizona where the genetic makeup of the interleukin 1B gene site is determined.
What does a positive test mean in terms of care? If your PST test is positive we may recommend that you have supportive therapy (also known as periodontal maintenance therapy) at shortened intervals, at minimum four times/year. We would closely monitor your periodontal status and if deep pockets persist or worsen surgical therapy followed by a stringent maintenance regimen may be the most effective treatment because it will produce the greatest reduction in Interleukin 1B production.
Genetic susceptibility testing is a new screening tool which could prove to be highly beneficial in predicting disease potential. The use of this test will enable us, as periodontists, to better tailor treatment and preventive regimens to individual needs.
We look forward to any questions you might have regarding this advance in periodontal diagnosis